Inflammasome activity is essential for homeostasis, but impaired and excessive activity causes a wide spectrum of human inflammatory disease, and therefore determining inflammasome activity during disease progression in vivo is important to advance our knowledge on the underlying disease pathologies and to develop novel therapies. Currently, however, no approaches exist to monitor and quantify inflammasome activity in vivo, and even ex vivo and in vitro measurements require prolonged manipulation of cells adverse affecting kinetic studies and further, require expensive substrates. We developed a novel dual reporter mouse model allowing luminescent and fluorescent-based in vivo and ex vivo detection and quantification of inflammasome activity without any manipulation.
In aim 1 we propose to characterize this novel model in vitro and in vivo, determine its specificity and contrast it with currently state of the art methods.
In aim 2 we propose to provide proof-of-principle for this novel model using two complex inflammasome-dependent diseases, namely Cryopyrinopathies (CAPS) and colitis. We expect these studies will ultimately positively affect human health by enabling novel, more relevant studies of inflammasome activity during physiology and pathology and further will be a very useful model for pre-clinical studies investigating inflammasome-targeted therapies.
Inflammasome activity is essential for homeostasis, but impaired and excessive activity causes a wide spectrum of human inflammatory disease, and therefore determining inflammasome activity during disease progression in vivo is important to advance our knowledge on disease pathologies and to develop and monitor efficacy of novel therapies. However, currently no approaches exist to monitor and quantify inflammasome activity in vivo, and even ex vivo/in vitro measurements require prolonged manipulation affecting kinetic studies and require expensive substrates. We developed a novel reporter mouse model allowing in vivo, ex vivo and in vitro detection and quantification of inflammasome activity without any manipulation, and propose to characterize this model and provide proof-of-principle using two complex inflammasome-dependent disease model, which we expect will positively affect human health by allowing novel, more relevant studies of inflammasome biology during pathology and will support future pre-clinical studies.
| Chu, Lan H; Indramohan, Mohanalaxmi; Ratsimandresy, Rojo A et al. (2018) The oxidized phospholipid oxPAPC protects from septic shock by targeting the non-canonical inflammasome in macrophages. Nat Commun 9:996 |
| Indramohan, Mohanalaxmi; Stehlik, Christian; Dorfleutner, Andrea (2018) COPs and POPs Patrol Inflammasome Activation. J Mol Biol 430:153-173 |
| Ratsimandresy, Rojo A; Chu, Lan H; Khare, Sonal et al. (2017) The PYRIN domain-only protein POP2 inhibits inflammasome priming and activation. Nat Commun 8:15556 |
| Ratsimandresy, Rojo A; Indramohan, Mohanalaxmi; Dorfleutner, Andrea et al. (2017) The AIM2 inflammasome is a central regulator of intestinal homeostasis through the IL-18/IL-22/STAT3 pathway. Cell Mol Immunol 14:127-142 |
| Khare, Sonal; Radian, Alexander D; Dorfleutner, Andrea et al. (2016) Measuring NLR Oligomerization I: Size Exclusion Chromatography, Co-immunoprecipitation, and Cross-Linking. Methods Mol Biol 1417:131-43 |
| de Almeida, Lucia; Dorfleutner, Andrea; Stehlik, Christian (2016) In vivo Analysis of Neutrophil Infiltration during LPS-induced Peritonitis. Bio Protoc 6: |
| de Almeida, Lucia; Dorfleutner, Andrea; Stehlik, Christian (2016) ASC-particle-induced Peritonitis. Bio Protoc 6: |
| Dorfleutner, Andrea; Stehlik, Christian (2016) A dRAStic RHOAdblock of Pyrin inflammasome activation. Nat Immunol 17:900-2 |
